1093818-24-6 Usage
General Description
The "GSK series" refers to a group of chemicals developed by GlaxoSmithKline, a multinational pharmaceutical and healthcare company. These chemicals are compounds that have been specifically designed and synthesized for various medical and scientific purposes, including drug discovery and development. The GSK series encompasses a wide range of molecules with diverse structures and functions, such as small molecule drugs, peptides, and biological agents. Many of these chemicals have undergone extensive testing and research for their potential therapeutic applications in treating various diseases and conditions, and some have been successfully developed into commercially available medications. The GSK series represents a significant contribution to the field of pharmaceutical chemistry and drug development, with the potential to impact healthcare and improve patient outcomes.
Check Digit Verification of cas no
The CAS Registry Mumber 1093818-24-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,9,3,8,1 and 8 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1093818-24:
(9*1)+(8*0)+(7*9)+(6*3)+(5*8)+(4*1)+(3*8)+(2*2)+(1*4)=166
166 % 10 = 6
So 1093818-24-6 is a valid CAS Registry Number.
1093818-24-6Relevant articles and documents
QUINAZOLINE DERIVATIVES AS PI3 KINASE INHIBITORS
-
, (2009/01/23)
Invented is a method of inhibiting the activity/function of P13 kinases using quinazoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinazoline derivatives.
